← 返回前沿论文

CPPs 对细胞扩增过程中原代人 NK 细胞 CQAs 的影响——一项使用实验设计的实验研究

英文原题:Impact of CPPs on primary human NK cell CQAs during cell expansion - an experimental study using design of experiments.

查看英文原题

Impact of CPPs on primary human NK cell CQAs during cell expansion - an experimental study using design of experiments.

PubMed 2026/07/27(内容时间) Front Bioeng Biotechnol Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

人类自然杀伤(NK)细胞是一种在免疫细胞治疗中具有前景的白细胞群体。血液系统肿瘤以及实体瘤已被证明对自体或异体NK细胞治疗有应答。提供数量充足且质量合格(即有效性、安全性、一致性、纯度和产量)的NK细胞仍然是一项挑战。为了理解和控制NK细胞生产,需要更深入地了解原代NK细胞培养的关键工艺参数(CPP)和关键质量属性(CQA)。由于潜在CPP数量众多,采用实验设计(DoE)方法进行系统性规划并减少实验数量。来自两名供者的原代NK细胞在批次条件下以及不同CPP条件下进行培养。对所研究的CPP的影响进行了详细分析,基于DoE的实验设置使得能够解释每个所选工艺参数及其组合对相关CQA的影响。基于这些数据,建立了统计模型,可预测最大活细胞数。该方法有助于深入了解CPP以及细胞治疗产品生产中可能的优化。

展开英文摘要原文

Human natural killer (NK) cells represent a promising leukocyte population for use in immune cell therapies. Hematologic as well as solid tumors have been shown to respond to treatment with autologous or allogeneic NK cells. Providing NK cells in sufficient quantity and quality (i. e. , efficacy, safety, identity, purity, and yield), remains a challenge. A deeper insight into the critical process parameters (CPP) and critical quality attributes (CQA) of primary NK cell culture is needed for the understanding and control of NK cell manufacturing. Due to the large number of potential CPP's, a design of experiments (DoE) approach was used for systematic planning and reduction of the number of experiments.

Primary NK cells from two donors were cultivated under batch conditions and varying CPP's. A detailed analysis of the impact of the investigated CPP's was conducted, and the DoE based experimental setup allowed the interpretation of the influence of each selected process parameter as well as their combination on the relevant CQAs.

Based on this data, a statistical model was formulated, which allows predictions of the maximal viable cell number. This approach allows for detailed insight into the CPP's and possible optimizations in the production of cell therapy products.

论文信息

作者
Mattert G、Schaffer C、Szarzynski A、von Werz V、Spadiut O、Pörtner R、Dammermann W
单位
Center for Translational Medicine, University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg an der Havel, Germany.Germany
期刊
Frontiers in bioengineering and biotechnology2026
原文标识
PubMed 42577276 · DOI 10.3389/fbioe.2026.1849836